FDA Approves New Treatment For Drug-Resistant TB; Activists Call For Affordable Access 19/08/2019 by Grace Ren The US Food and Drug Administration (FDA) last week approved a tuberculosis (TB) treatment regimen containing a new drug, pretomanid, offering a shorter, more effective course of treatment for highly drug-resistant strains of TB, the world’s leading cause of death by infectious disease. Pretomanid is only the third TB drug to be approved in over […] Continue reading -> FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis 15/08/2019 by Press release [TB Alliance] NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) […] Continue reading -> How To Fix The Medical R&D Model 14/08/2019 by David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Climate Change May Be Responsible For The Rise Of Deadly Fungus Candida Auris 06/08/2019 by David Branigan A new study suggests that the deadly drug-resistant fungus, Candida auris, may have adapted to warmer ambient temperatures caused by climate change, enabling it to survive in human body temperatures and infect humans with weakened immune systems, primarily in hospitals. The study, published in the journal of The American Society for Microbiology in July, posits […] Continue reading -> React Africa 2019: Universal Health Coverage Can Help Combat Antimicrobial Resistance 25/07/2019 by Geoffrey Kamadi NAIROBI – Neonatal sepsis is one of the leading causes of newborn deaths globally, and increasing pathogen resistance to available first-line treatments is a prime example of rising antimicrobial resistance. That is why the Global Antibiotic Research and Development Partnership (GARDP) – a non-profit research organisation that develops new or improved antibiotic treatments – is […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 by Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 by Editorial team WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 by Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> EU Calls For Results Of All EU-based Clinical Trials To Be Added To Public Database 04/07/2019 by David Branigan The European Commission and European Union medicines regulatory agencies sent an open letter to all sponsors of EU-based clinical trials to remind them of their obligation to publish the results of the trials – both positive and negative – in a public database. The open letter by the European Commission (EC), the European Medicines Agency […] Continue reading -> GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 by David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis 15/08/2019 by Press release [TB Alliance] NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) […] Continue reading -> How To Fix The Medical R&D Model 14/08/2019 by David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Climate Change May Be Responsible For The Rise Of Deadly Fungus Candida Auris 06/08/2019 by David Branigan A new study suggests that the deadly drug-resistant fungus, Candida auris, may have adapted to warmer ambient temperatures caused by climate change, enabling it to survive in human body temperatures and infect humans with weakened immune systems, primarily in hospitals. The study, published in the journal of The American Society for Microbiology in July, posits […] Continue reading -> React Africa 2019: Universal Health Coverage Can Help Combat Antimicrobial Resistance 25/07/2019 by Geoffrey Kamadi NAIROBI – Neonatal sepsis is one of the leading causes of newborn deaths globally, and increasing pathogen resistance to available first-line treatments is a prime example of rising antimicrobial resistance. That is why the Global Antibiotic Research and Development Partnership (GARDP) – a non-profit research organisation that develops new or improved antibiotic treatments – is […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 by Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 by Editorial team WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 by Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> EU Calls For Results Of All EU-based Clinical Trials To Be Added To Public Database 04/07/2019 by David Branigan The European Commission and European Union medicines regulatory agencies sent an open letter to all sponsors of EU-based clinical trials to remind them of their obligation to publish the results of the trials – both positive and negative – in a public database. The open letter by the European Commission (EC), the European Medicines Agency […] Continue reading -> GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 by David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
How To Fix The Medical R&D Model 14/08/2019 by David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Climate Change May Be Responsible For The Rise Of Deadly Fungus Candida Auris 06/08/2019 by David Branigan A new study suggests that the deadly drug-resistant fungus, Candida auris, may have adapted to warmer ambient temperatures caused by climate change, enabling it to survive in human body temperatures and infect humans with weakened immune systems, primarily in hospitals. The study, published in the journal of The American Society for Microbiology in July, posits […] Continue reading -> React Africa 2019: Universal Health Coverage Can Help Combat Antimicrobial Resistance 25/07/2019 by Geoffrey Kamadi NAIROBI – Neonatal sepsis is one of the leading causes of newborn deaths globally, and increasing pathogen resistance to available first-line treatments is a prime example of rising antimicrobial resistance. That is why the Global Antibiotic Research and Development Partnership (GARDP) – a non-profit research organisation that develops new or improved antibiotic treatments – is […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 by Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 by Editorial team WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 by Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> EU Calls For Results Of All EU-based Clinical Trials To Be Added To Public Database 04/07/2019 by David Branigan The European Commission and European Union medicines regulatory agencies sent an open letter to all sponsors of EU-based clinical trials to remind them of their obligation to publish the results of the trials – both positive and negative – in a public database. The open letter by the European Commission (EC), the European Medicines Agency […] Continue reading -> GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 by David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Climate Change May Be Responsible For The Rise Of Deadly Fungus Candida Auris 06/08/2019 by David Branigan A new study suggests that the deadly drug-resistant fungus, Candida auris, may have adapted to warmer ambient temperatures caused by climate change, enabling it to survive in human body temperatures and infect humans with weakened immune systems, primarily in hospitals. The study, published in the journal of The American Society for Microbiology in July, posits […] Continue reading -> React Africa 2019: Universal Health Coverage Can Help Combat Antimicrobial Resistance 25/07/2019 by Geoffrey Kamadi NAIROBI – Neonatal sepsis is one of the leading causes of newborn deaths globally, and increasing pathogen resistance to available first-line treatments is a prime example of rising antimicrobial resistance. That is why the Global Antibiotic Research and Development Partnership (GARDP) – a non-profit research organisation that develops new or improved antibiotic treatments – is […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 by Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 by Editorial team WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 by Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> EU Calls For Results Of All EU-based Clinical Trials To Be Added To Public Database 04/07/2019 by David Branigan The European Commission and European Union medicines regulatory agencies sent an open letter to all sponsors of EU-based clinical trials to remind them of their obligation to publish the results of the trials – both positive and negative – in a public database. The open letter by the European Commission (EC), the European Medicines Agency […] Continue reading -> GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 by David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
React Africa 2019: Universal Health Coverage Can Help Combat Antimicrobial Resistance 25/07/2019 by Geoffrey Kamadi NAIROBI – Neonatal sepsis is one of the leading causes of newborn deaths globally, and increasing pathogen resistance to available first-line treatments is a prime example of rising antimicrobial resistance. That is why the Global Antibiotic Research and Development Partnership (GARDP) – a non-profit research organisation that develops new or improved antibiotic treatments – is […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 by Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 by Editorial team WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 by Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> EU Calls For Results Of All EU-based Clinical Trials To Be Added To Public Database 04/07/2019 by David Branigan The European Commission and European Union medicines regulatory agencies sent an open letter to all sponsors of EU-based clinical trials to remind them of their obligation to publish the results of the trials – both positive and negative – in a public database. The open letter by the European Commission (EC), the European Medicines Agency […] Continue reading -> GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 by David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 by Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 by Editorial team WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 by Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> EU Calls For Results Of All EU-based Clinical Trials To Be Added To Public Database 04/07/2019 by David Branigan The European Commission and European Union medicines regulatory agencies sent an open letter to all sponsors of EU-based clinical trials to remind them of their obligation to publish the results of the trials – both positive and negative – in a public database. The open letter by the European Commission (EC), the European Medicines Agency […] Continue reading -> GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 by David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New Cancer Drugs Top Entries On WHO Essential Medicines List 09/07/2019 by Editorial team WHO has added ten new cancer drugs, including some pricey ones, to its 2019 Essential Medicines List, which provides global guidance to countries and health systems about drugs deemed most essential to patients and public health systems. The addition of major new cancer treatments in five categories, melanoma (skin), lung, blood and prostate cancers, reflects […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 by Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> EU Calls For Results Of All EU-based Clinical Trials To Be Added To Public Database 04/07/2019 by David Branigan The European Commission and European Union medicines regulatory agencies sent an open letter to all sponsors of EU-based clinical trials to remind them of their obligation to publish the results of the trials – both positive and negative – in a public database. The open letter by the European Commission (EC), the European Medicines Agency […] Continue reading -> GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 by David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
“Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 by Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> EU Calls For Results Of All EU-based Clinical Trials To Be Added To Public Database 04/07/2019 by David Branigan The European Commission and European Union medicines regulatory agencies sent an open letter to all sponsors of EU-based clinical trials to remind them of their obligation to publish the results of the trials – both positive and negative – in a public database. The open letter by the European Commission (EC), the European Medicines Agency […] Continue reading -> GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 by David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
EU Calls For Results Of All EU-based Clinical Trials To Be Added To Public Database 04/07/2019 by David Branigan The European Commission and European Union medicines regulatory agencies sent an open letter to all sponsors of EU-based clinical trials to remind them of their obligation to publish the results of the trials – both positive and negative – in a public database. The open letter by the European Commission (EC), the European Medicines Agency […] Continue reading -> GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 by David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 04/07/2019 by David Branigan The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading -> Posts navigation Older posts